Admera Taps N-of-One for Clinical Interpretation of OncoGxOne Oncology Panel | GenomeWeb

NEW YORK (GenomeWeb) – N-of-One announced today that it has signed an agreement with molecular diagnostics company Admera Health to provide clinical interpretation for patients tested with Admera's OncoGxOne 64-gene oncology panel.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.